Keywords: wilex, wx-671, enters, clinic, ag, germany, initiated

Wilex' WX-671 enters clinic

Article | 27 September 2004

Print This

Wilex AG of Germany has initiated a Phase I trial of its new oral, non-cytotoxic anticancer compound WX-671. The open-label, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in